Evidence map›Paper›PMID 20861254›Full record

ArticleJournal of virology2010

The Epstein-Barr virus BZLF1 protein inhibits tumor necrosis factor receptor 1 expression through effects on cellular C/EBP proteins.

Jillian A Bristol, Amanda R Robinson, Elizabeth A Barlow, Shannon C Kenney

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Jillian A BristolDepartment of Oncology (McArdle Laboratory for Cancer Research), University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706, USA.
Amanda R Robinson
Elizabeth A Barlow
Shannon C Kenney
Bipar · FRUniversity of Wisconsin–Madison · US

Funding

Visualizing EBV and HCMV DNA Dynamics During InfectionP01CA022443 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI WILLIAM M. SUGDEN · 1985 to 2026
$53.1M
Training in Cancer Biology Training GrantT32CA009135 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SUGDEN, WILLIAM M. · 1985 to 2024
$10.4M
REGULATION OF THE EBV BRLF1 AND BZLF1 PROMOTERSR01CA058853 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KENNEY, SHANNON CELESTE · 1993 to 2013
$3.9M
GENE THERAPY FOR AIDS RELATED CNS LYMPHOMASR01CA066519 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KENNEY, SHANNON CELESTE · 1995 to 2012
$3.7M
NCI NIH HHS P01 CA022443NCI NIH HHS P01-CA022443NCI NIH HHS R01 CA058853NCI NIH HHS R01 CA066519NCI NIH HHS R01-CA58853NCI NIH HHS R01-CA66519NCI NIH HHS T32 CA009135
6 · The paper itself

Abstract

The Epstein-Barr virus immediate-early protein, BZLF1 (Z), initiates the switch between latent and lytic infection and plays an essential role in mediating viral replication. Z also inhibits expression of the major receptor for tumor necrosis factor (TNF), TNFR1, thus repressing TNF cytokine signaling, but the mechanism for this effect is unknown. Here, we demonstrate that Z prevents both C/EBPα- and C/EBPβ-mediated activation of the TNFR1 promoter (TNFR1p) by interacting directly with both C/EBP family members. We show that Z interacts directly with C/EBPα and C/EBPβ in vivo and that a Z mutant altered at alanine residue 204 in the bZIP domain is impaired for the ability to interact with both C/EBP proteins. Furthermore, we find that the Z(A204D) mutant is attenuated in the ability to inhibit the TNFR1p but mediates lytic viral reactivation and replication in vitro in 293 cells as well as wild-type Z. Although Z does not bind directly to the TNFR1p in EMSA studies, chromatin immunoprecipitation studies indicate that Z is complexed with this promoter in vivo. The Z(A204D) mutant has reduced interaction with the TNFR1p in vivo but is similar to wild-type Z in its ability to complex with the IL-8 promoter. Finally, we show that the effect of Z on C/EBPα- and C/EBPβ-mediated activation is promoter dependent. These results indicate that Z modulates the effects of C/EBPα and C/EBPβ in a promoter-specific manner and that in some cases (including that of the TNFR1p), Z inhibits C/EBPα- and C/EBPβ-mediated activation.

Indexed as

CCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding Protein-betaChromatin ImmunoprecipitationElectrophoretic Mobility Shift AssayHeLa CellsHerpesvirus 4, HumanHumansImmunoblottingImmunoprecipitationMutagenesisPromoter Regions, GeneticReceptors, Tumor Necrosis Factor, Type ITrans-ActivatorsVirus ActivationVirus ReplicationBZLF1 protein, Herpesvirus 4, HumanCCAAT-Enhancer-Binding Protein-alphaCCAAT-Enhancer-Binding Protein-betaReceptors, Tumor Necrosis Factor, Type ITrans-Activators

Identifiers

PMID20861254
PMCPMC2976414
OpenAlexW1984820123

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.